• 原料直供
• 试剂商城
• 直接询价

分类

• {SNA} A to C, A-AM, Bioactive Small Molecules, Biochemicals and Reagents, Cell Biology, Chymotrypsin, α-, Chymotrypsin, alpha-, Coagulation Proteins and Reagents, Enzyme Inhibitors, Enzyme Inhibitors by Enzyme, Enzymes, Inhibitors, and Substrates, Inhibitors, P to Q, Plasma & Blood Proteins, Plasmin, Protease Inhibitor Specificity Index, Protease Inhibitors, Proteins and Derivatives
• {SNA} A to C, A-AM, Bioactive Small Molecules, Biochemicals and Reagents, Chymotrypsin, α-, Chymotrypsin, alpha-, Coagulation Proteins and Reagents,
• {SNA} C

产品应用

• EACA is directly soluble in water at 25 mg/ml. As an inhibitor of plasmin it is has been utilized in the clotting buffer for fibrinogen assays. This buffer is 10 mM potassium and sodium phosphate, pH 6.4, with 0.20 g CaCl2, 5 g 6-Aminohexanoic acid, 1 g sodium azide, and 9 g NaCl in 1 liter. The buffer is stable indefinitely at room temperature.

相关文献及参考

• Ohta ,S. et al.: Chem. Pharm. Bull., 28, 1917 (1980); Shagger, H. et al.: Anal. Biochem., 199, 223 (1991); Soter, N.A. et al.: J. Immunol., 114, 928 (1975);
• Has been recommended as a reagent for the extraction of aldehydes from reaction mixtures, giving better recovery than bisulfite: Chem. Pharm. Bull., 28, 1917 (1980).
• Short: III/35B
• 3. Adelman, B., et al., Plasminogen interactions with platelets in plasma. Blood 72 , 1530-1535, (1988)
• 2. Krishnamurti, C., et al., Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis. Thromb. Res. 73 , 419-430, (1994) 摘要
• 6. H. Schägger, G. von Jagow Anal. Biochem. 199 , 223, (1991) 摘要
• Merck 14 ,432

安全信息

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Multiple routes
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 14400 mg/kg/59D-I
TOXIC EFFECTS :
   Behavioral - muscle weakness
   Kidney, Ureter, Bladder - hematuria
REFERENCE :
   BJURAN British Journal of Urology.  (Longman Group Ltd., POB 11318,
   Birmingham, AL 35202) V.1-    1929-  Volume(issue)/page/year: 60,81,1987

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 7 gm/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   PHMCAA Pharmacologist.  (American Soc. for Pharmacology and Experimental
   Therapeutics, 9650 Rockville Pike, Bethesda, MD 20014)  V.1-    1959-
   Volume(issue)/page/year: 3,62,1961

TYPE OF TEST            : LD - Lethal dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : >10 gm/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   PHMCAA Pharmacologist.  (American Soc. for Pharmacology and Experimental
   Therapeutics, 9650 Rockville Pike, Bethesda, MD 20014)  V.1-    1959-
   Volume(issue)/page/

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 1778 mg/kg/8D-I
TOXIC EFFECTS :
   Kidney, Ureter, Bladder - changes in tubules (including acute renal failure,
   acute tubular necrosis)
   Kidney, Ureter, Bladder - hematuria
   Nutritional and Gross Metabolic - body temperature increase
REFERENCE :
   AJKDDP American Journal of Kidney Diseases.  (Grune & Stratton, Inc.,
   Journal Subscription Dept., POB 6280, Duluth, MN 55806)  V.1-    1981-
   Volume(issue)/page/year: 8,441,1986

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 153 gm/kg
SEX/DURATION            : female 40 day(s) pre-mating
                          female 1-21 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Fertility - female fertility index (e.g. # females pregnant
   per # sperm positive females; # females pregnant per # females mated)
REFERENCE :
   APTOA6 Acta Pharmacologica et Toxicologica.  (Copenhagen, Denmark)  V.1-59,
   1945-86.  For publisher information, see PHTOEH  Volume(issue)/page/year:
   22,340,1965

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 190 gm/kg
SEX/DURATION            : male 38 day(s) pre-mating
TOXIC EFFECTS :
   Reproductive - Fertility - male fertility index (e.g. # males impregnating
   females per # males exposed to fertile nonpregnant females)
REFERENCE :
   APSXAS Acta Pharmaceutica Suecica.  (Apotekarsocieteten-Farmacevtiska
   Foereningen, Box 1136, S-111, 81 Stockholm, Sweden)  V.1-    1964-
   Volume(issue)/page/year: 3,115,1966

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intrauterine
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 15 mg/kg
SEX/DURATION            : female 6 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Fertility - post-implantation mortality (e.g. dead and/or
   resorbed implants per total number of implants)
REFERENCE :
   BIREBV Biology of Reproduction.  (Soc. for the Study of Reproduction, 309 W.
   Clark St., Champaign, IL 61820)  V.1-    1969-  Volume(issue)/page/year:
   23,553,1980

其他信息

• 止血药:6-氨基己酸又称氨己酸、氨基己酸、ε-氨基己酸、抗血纤溶酸，为SAH常用的抗纤溶酶止血药，具有抗纤溶的作用，能与纤溶酶原激活物产生竞争性抑制，使纤溶酶原转变成纤溶酶的过程受到抑制，对纤溶酶也有较弱的直接抑制作用，减慢纤维蛋白裂解成为多肽和氨基酸。本品在血中的浓度达到130mg/L以上才能抑制纤溶酶原转变为纤溶酶，直接抑制纤溶酶须达到1300mg/L，从而抑制纤维蛋白的溶解，达到止血作用。其作用较弱，排泄快，维持时间短。本药在胃肠内吸收迅速、完全，生物利用度为80%。服后2小时血药浓度达峰值。大部分以原型经尿排泄，t1/2约为103分钟。适用于原发性或继发性纤溶亢进所致的出血，如严重感染、妇科意外、白血病、恶性肿瘤和重症肝病等引起的出血; 其他如外科大手术出血，妇产科出血，肺、上消化道、前列腺、肝、胰等出血。外科手术中或术前用药，可减少术中渗血，并减少输血量。 6-氨基己酸与止血环酸(AMCA)和对羟基苄胺(PAMBA)是目前临床上常用的抗纤维蛋白溶解剂。它们均能抑制纤维蛋白溶解酶的激活因子，使前者不能激活而成为纤维蛋白溶酶，从而延长堵塞破口血凝块的溶解期限，减少等待手术期间再出血的机会。因为在蛛网膜下腔出血后脑脊液中的纤维蛋白酶活性增强，故抗纤溶治疗是有必要的。多数研究人员认为6-氨基己酸及止血环酸防止近期再出血的效果较好，并且应用越早效果越好。
• 方法一:己内酰胺水解而得。将己内酰胺、浓盐酸和3倍量蒸馏水加入反应罐内，搅拌，升温回流1.5h，控制温度103-106℃。反应毕，测定转化率应达95%以上。加蒸馏水稀释成10%浓度，得10%6-氨基己酸水解液。将水解液以每小时5-10L的流速均匀地流入离子交换柱[装001×7（732#）强酸性苯乙烯系阳离子交换树脂]，进行吸附。流完后关闭出口，浸泡过夜。用蒸馏水洗涤离子交换柱，洗去盐酸（检查流出液至无氯离子）。然后，以每小时5-10L流速均匀流入3.5%氢氧化铵。流完后关闭流出口，浸泡过夜。次日继续边完氢氧化铵后，流入蒸馏水进行洗脱，收集含有6-氨基己酸的洗脱液。加活性炭脱色，过滤，滤液于47-70℃减压浓缩近干。趁热加入乙醇，搅拌析出结晶。冷却后甩滤得粗品。将粗品溶于蒸馏水，加活性炭在60℃脱色1h。趁热过滤。滤液减压浓缩近干。加乙醇析出结晶，冷却，甩滤，结晶用乙醇洗涤，干燥，得6-氨基己酸。对己内酸胺的总收率为75-80%。
• Acros Organics:6-氨基己酸 6-Aminocaproic acid, 99+%(60-32-2)
• MOL 文件:60-32-2.mol
• 储运特性:库房通风低温干燥
• {Chemic
• 下游产品:甲磺酸加贝酯 --> 克
• 刺激数据:眼睛-兔子 500 毫克/24小时轻度
• 无气味。味苦
• TCI Shanghai:6-氨基正己酸 6-Aminohexanoic Acid,>;98.0%(T)(60-32-2)
• 适应症与用法用量:抗纤维蛋白溶解药，临床主要用于预防及治疗血纤维蛋白溶解亢进引起的各种出血。口服：每次2g，每日3～4次，依病情用7～10日或更久; 小儿每次0.1g/kg，每日3～4次。本品吸收迅速完全，服后1～2小时可达血中有效浓度。静滴：初始剂量4.0～6.0g，30分钟内滴完，维持剂量1.0g/h，一日剂量不超过20g。 用于防治原发性纤溶亢进和弥漫性血管内凝血的继发性纤溶亢进引起的各种出血。也可用于脑、肺、前列腺、甲状腺、肾上腺、子宫等手术出血，以
• 理化性质:化学式H2NCH2(CH2)3CH2COOH。分子量131.18。由乙醚中得叶片晶体。无臭，味苦。熔点202～207℃(分解)。溶于水，微溶于甲醇，不溶于乙醇、乙醚、氯仿。pK1＝4.43、pK2＝10.75。用碱性KMnO4溶液氧化生成己二酸，6-氨基己酸与HNO2作用得到5-己烯酸和4-己烯酸，与脲和氢氧化钡水溶液一起煮沸生成6-脲基己酸，与ROH作用成酯，与RCOCl反应氨基上导入酰基。制法：由6-(N-苯甲酰氨基)己腈在盐酸存在下水解获得，或由己内酰胺在盐酸存在下水解，再用氢氧化铵处理制得。用途：用于有机合成。作抗纤维朊溶酶试剂。用作止血药。对因纤维蛋白溶解活性增高而引起的某些严重出血有明显疗效。适用于多种外科手术时的渗血或局部出血。也用于咯血、消化道出血及妇产科出血性疾患等。
• 检测方法:T,NMR